BioNTech SE, a Mainz-based German biotech firm, confronts a homegrown lawsuit seeking compensation for purported COVID-19 vaccine side effects. The initial case, scheduled for court on June 12, is expected to precipitate nationwide litigation.
BioNTech is set to attend the first court hearing on Monday, June 12. It will go to court to defend itself from the first case filed by a German woman who allegedly suffered from side effects after receiving her COVID-19 jab. She is seeking damages, and more cases are expected to be filed across the country after this.
According to Reuters, the plaintiff is suing the biotech firm and asking for at least €150,000 or about $161,500 in damages. The regional court in Hamburg said that in her lawsuit, the woman said the amount is for bodily harm and other material damages that were not specified.
For this case, she is being represented by Rogert & Ulbrich law firm. She claimed that after the jab, she suffered from pains in the upper part of her body, developed a sleeping disorder, fatigue, and swollen extremities. Her lawyer, Tobias Ulbrich, told the publication that will challenge the assessment made by European Union regulators and the vaccine assessment bodies in Germany that said the BioNTech vaccine has positive benefits.
In any case, it was mentioned that under German pharmaceutical law, drug or vaccine makers are only liable to give compensation for side effects if medical science shows that their products bear incorrect information or have caused disproportionate harm commensurate to their benefits.
With this, BioNTech believes that after a careful review and consideration of the case, it concluded that the lawsuit holds no merit. It also noted that the same vaccine was already received by some 1.5 billion people around the world, including more than 64 million Germans.
Meanwhile, despite BioNTech’s statements, Financial Times reported that the law firm representing the woman insisted that the burden of proof and the possible compensation is lower in Germany. Thus, it is confident that their case against BioNTech is strong.
Photo: Mat Napo/Unsplash


GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns
US Auto Industry Urges Trump to Block Chinese EV Market Access
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears
Armani Group Eyes Strategic Stake Sale to Luxury Giants
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility
KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices
Debate over H-1B visas shines spotlight on US tech worker shortages 



